Old Web
English
Sign In
Acemap
>
authorDetail
>
Rajesh R. Kaldate
Rajesh R. Kaldate
Exelixis
Medicine
Pathology
Gastroenterology
Internal medicine
Dosing
5
Papers
13
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).
2019
Journal of Clinical Oncology
Robin Kate Kelley
Lorenza Rimassa
Baek-Yeol Ryoo
Joong-Won Park
Jean Frédéric Blanc
Stephen Lam Chan
Vincenzo Dadduzio
Thomas Yau
Suvajit Sen
David Markby
Rajesh R. Kaldate
Anthony B. El-Khoueiry
Ann-Lii Cheng
Tim Meyer
Ghassan K. Abou-Alfa
Show All
Source
Cite
Save
Citations (7)
Founder mutation versus full sequencing of MYH for increasing clinical sensitivity.
2013
Journal of Clinical Oncology
Sophia Ceulemans
Christopher Arnell
Lynn Anne Burbidge
Brian L. Abbott
Rajesh R. Kaldate
Michelle Landon
Show All
Source
Cite
Save
Citations (0)
BSA dosing and suboptimal 5-FU exposure among colorectal cancer patients of varying gender and age.
2012
Journal of Clinical Oncology
Abebe Haregewoin
Stephanie A. Hamilton
Charles E. Grier
Rajesh R. Kaldate
Show All
Source
Cite
Save
Citations (2)
Mutation analysis of PALB2 in high-risk and lower-risk patients negative for BRCA1 and BRCA2 mutations.
2012
Journal of Clinical Oncology
Shelly Cummings
Jenny Peterson
Elisha Hughes
Rajesh R. Kaldate
Sonia. Chen
Jeffrey Trost
Christopher Arnell
Jennifer Saam
Benjamin B. Roa
Priscilla H. Fernandes
Show All
Source
Cite
Save
Citations (3)
Modeling 5-FU AUC-dose relationship to develop a PK dosing algorithm.
2011
Journal of Clinical Oncology
Abebe Haregewoin
Rajesh R. Kaldate
Stephanie A. Hamilton
Jennifer Saam
Richard J. Wenstrup
Show All
Source
Cite
Save
Citations (1)
1